Revelation Biosciences, Inc. Unit
REVBU
REVBU was delisted on the 11th of January, 2023.
11 hedge funds and large institutions have $23.3M invested in Revelation Biosciences, Inc. Unit in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$10.5M |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$3.55M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$3.05M |
| 4 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$2.38M |
| 5 |
Walleye Capital
New York
|
+$738K |
Top Sellers
REVBU Hedge Fund Activity: Q4 2020 in Review
11 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences, Inc. Unit (REVBU) for Q4 2020, worth a combined $23.3M.
Buyers outnumbered sellers: 11 funds opened new REVBU positions and 0 closed out — a net gain of 11 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Glazer Capital LLC, opening a new position worth an estimated $10.5M.
- 11 institutional investors held Revelation Biosciences, Inc. Unit (REVBU) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $23.3M of Revelation Biosciences, Inc. Unit stock for Q4 2020.
- 11 funds opened new Revelation Biosciences, Inc. Unit positions in Q4 2020 and 0 closed out, a net change of +11 holders.
- The largest Revelation Biosciences, Inc. Unit buyer in Q4 2020 was Glazer Capital LLC, an estimated $10.5M added.
Based on aggregated 13F filings for Q4 2020.